American Academy of Dermatology 2026—Highlights with a Pediatric Dermatology Focus
Résumé
The 2026 annual meeting of the American Academy of Dermatology (AAD) was held in Denver, Colorado, from March 27–31. As expected, the meeting featured the presentation of new data and generated ongoing excitement about therapies and approaches aimed at optimizing our care of patients. This article summarizes several key takeaways, with a focus on those relevant to pediatric dermatology.
Références
Efficacy and safety of monotherapy amlitelimab, a Non-depleting anti-OX40 ligand antibody, in moderate-to-severe atopic dermatitis: 24-week results from the pivotal COAST-1 and COAST-2 phase 3 trials. American Academy of Dermatology Annual Meeting; 2026 March 27–31, 2026; Denver, Colorado.
Efficacy and safety of amlitelimab, a nondepleting anti-OX40 ligand antibody, in combination with topical therapy in participants with moderate-to-severe atopic dermatitis: 24-week results from the SHORE phase 3 trial. American Academy of Dermatology Annual Meeting; 2026 March 27–31, 2026; Denver, Colorado.
Byun M, Ma CS, Akçay A, Pedergnana V, Palendira U, Myoung J, et al. Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med. 2013;210(9):1743–1759. doi:10.1084/jem.20130592
Fu L, Tian T, Wang B, Lu Z, Gao Y, Sun Y, et al. Global patterns and trends in Kaposi sarcoma incidence: a population-based study. Lancet Glob Health. 2023;11(10):e1566–e1575. doi:10.1016/S2214-109X(23)00349-2
INTEGUMENT-INFANT: Once-Daily Roflumilast Cream 0.05% in Infants Aged 3–<24 Months With Atopic Dermatitis. American Academy of Dermatology Annual Meeting; 2026 March 27–31, 2026; Denver, Colorado.
Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthritis Rheumatol. Published online March 28, 2026. doi:10.1002/art.70134
Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, et al. Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. J Am Acad Dermatol. 2026;94(3):802–809. doi:10.1016/j.jaad.2025.11.033
Soung J LM, Hebert A, Pink AE, Shi Y, Miller-Kassamali M, Cafone J, Jiang J, Li S, Yang YW, Eichenfield L. Durability of icotrokinra (targeted oral peptide) effects in adolescents with moderate-to-severe plaque psoriasis: one-year results from the ICONIC-LEAD Study. American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, Colorado.
Zuberbier T, Abdul Hameed Ansari Z, Abdul Latiff AH, Abuzakouk MM, Agcaoili-De Jesus MS, Agondi RC, et al. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. Published online February 6, 2026. doi:10.1111/all.70210
Rachubinski AL, Wallace E, Gurnee E, Enriquez-Estrada BA, Worek KR, Smith KP, et al. JAK inhibition decreases the autoimmune burden in Down syndrome. eLife. 2024;13:RP99323. doi:10.7554/eLife.99323
Role of semaglutide in restoring ovulation in youth and adults with polycystic ovary syndrome (Restore) [Internet]. ClinicalTrials.gov Identifier: NCT05819853. 2026 [cited 2026 Apr 5]. Available from: https://clinicaltrials.gov/study/NCT05819853.
A study to investigate the pharmacokinetics and safety of dupilumab in participants ≥2 years to <12 years of age with uncontrolled chronic spontaneous urticaria (CSU) (LIBERTY-CSU CUPIDKids) [Internet]. ClinicalTrials.gov Identifier: NCT05526521. 2025 [cited 2026 Apr 29]. Available from: https://clinicaltrials.gov/study/NCT05526521.
Lallas A, Moscarella E, Longo C, Kyrgidis A, de Mestier Y, Vale G, et al. Likelihood of finding melanoma when removing a Spitzoid-looking lesion in patients aged 12 years or older. J Am Acad Dermatol. 2015;72(1):47–53. doi:10.1016/j.jaad.2014.09.037
Ablon G. A 7-Week, Open-Label Study Evaluating the Efficacy and Safety of 415-nm/633-nm Phototherapy for Treating Mild-to-Moderate Acne in Adolescents and Adults. J Clin Aesthet Dermatol. 2025;18(10):25–32.
Lampert S, Sandhu A, Ilyas EN. Hormonal versus copper intrauterine devices: a retrospective analysis of association with androgen-related dermatologic disorders using the TriNetX database. J Am Acad Dermatol. 2026;94(2):707–708. doi:10.1016/j.jaad.2025.10.088
Kaneko S, Mizuta M, Hatano M, Shimbo A, Irabu H, Yatabe R, et al. Distinct cytokine signature in juvenile dermatomyositis: linking myositis-specific antibodies and clinical manifestations. Cytokine. 2026;197:157070. doi:10.1016/j.cyto.2025.157070
Pandya AG, Lynde CW, Shayesteh Alam M, Thorla IH, Reed K, Green LJ, et al. Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo. J Invest Dermatol. Published online December 11, 2025. doi:10.1016/j.jid.2025.11.016
Yamaguchi Y, Peeva E, Adiri R, Ghosh P, Napatalung L, Hamzavi I, et al. Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study. J Am Acad Dermatol. 2025;92(4):781–789. doi:10.1016/j.jaad.2024.11.064
